Literature DB >> 1400646

Viability of neocortical function shown in behavioral activation state PET studies in Alzheimer disease.

R Duara1, W W Barker, J Chang, F Yoshii, D A Loewenstein, S Pascal.   

Abstract

Twenty subjects with mildly to moderately severe Alzheimer disease (AD) and 14 normal elderly control subjects were studied using [18F]fluorodeoxyglucose and positron emission tomography (PET) to investigate regional cerebral glucose metabolism during both a resting state and a behavioral activation state, utilizing a reading memory task (RMT). The RMT produced significant global metabolic activation of 15 +/- 15% in normal subjects and 11 +/- 13% in AD subjects. The occipital regions were preferentially activated, but all regions in both groups were also significantly activated. The RMT did not allow a better discrimination of AD patients from normal controls on the basis of regional metabolic deficits. Regions in the AD group that were individually classified as hypometabolic during rest also exhibited metabolic activation. The apparent viability of hypometabolic regions in AD patients challenges current hypotheses regarding the cause of abnormal metabolism in AD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400646     DOI: 10.1038/jcbfm.1992.129

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  9 in total

Review 1.  A meta-analysis of structural and functional brain imaging in dementia of the Alzheimer's type: a neuroimaging profile.

Authors:  Konstantine K Zakzanis; Simon J Graham; Zachariah Campbell
Journal:  Neuropsychol Rev       Date:  2003-03       Impact factor: 7.444

Review 2.  Brain fuel metabolism, aging, and Alzheimer's disease.

Authors:  Stephen Cunnane; Scott Nugent; Maggie Roy; Alexandre Courchesne-Loyer; Etienne Croteau; Sébastien Tremblay; Alex Castellano; Fabien Pifferi; Christian Bocti; Nancy Paquet; Hadi Begdouri; M'hamed Bentourkia; Eric Turcotte; Michèle Allard; Pascale Barberger-Gateau; Tamas Fulop; Stanley I Rapoport
Journal:  Nutrition       Date:  2010-10-29       Impact factor: 4.008

Review 3.  In vivo characterization of traumatic brain injury neuropathology with structural and functional neuroimaging.

Authors:  Brian Levine; Esther Fujiwara; Charlene O'Connor; Nadine Richard; Natasa Kovacevic; Marina Mandic; Adriana Restagno; Craig Easdon; Ian H Robertson; Simon J Graham; Gordon Cheung; Fuqiang Gao; Michael L Schwartz; Sandra E Black
Journal:  J Neurotrauma       Date:  2006-10       Impact factor: 5.269

4.  Effects of m-chlorophenylpiperazine on regional brain glucose utilization: a positron emission tomographic comparison of alcoholic and control subjects.

Authors:  D Hommer; P Andreasen; D Rio; W Williams; U Ruttimann; R Momenan; A Zametkin; R Rawlings; M Linnoila
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

5.  A pilot study evaluating the efficacy and safety of rivastigmine in patients with mixed dementia.

Authors:  Steven G Potkin; Gus Alva; Ibrahim Gunay; Barbara Koumaras; Michael Chen; Dario Mirski
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

6.  Changes in local cerebral blood flow by neuroactivation and vasoactivation in patients with impaired cognitive function.

Authors:  W H Knapp; C Dannenberg; B Marschall; D Zedlick; K Löschmann; S Bettin; H Barthel; A Seese
Journal:  Eur J Nucl Med       Date:  1996-08

7.  Functional reorganisation of memory after traumatic brain injury: a study with H(2)(15)0 positron emission tomography.

Authors:  B Levine; R Cabeza; A R McIntosh; S E Black; C L Grady; D T Stuss
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-08       Impact factor: 10.154

8.  Intermittent hypoxia training protects cerebrovascular function in Alzheimer's disease.

Authors:  Eugenia B Manukhina; H Fred Downey; Xiangrong Shi; Robert T Mallet
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-10

9.  Strategies for molecular imaging dementia and neurodegenerative diseases.

Authors:  Bernhard J Schaller
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.